(Q39691780)

English

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.

scientific article published on 17 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Annette Hayden

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

0 references

publication date

17 June 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

127

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

109-119

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556507%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

https://scigraph.springernature.com/pub.10.1007/s10549-010-0982-0

0 references

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Roles of the EZH2 histone methyltransferase in cancer epigenetics

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Polycomb group protein complexes: do different complexes regulate distinct target genes?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Polycomb group protein ezh2 controls actin polymerization and cell signaling.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

The Polycomb group protein EZH2 directly controls DNA methylation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

The polycomb-group gene Ezh2 is required for early mouse development

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Nile red: a selective fluorescent stain for intracellular lipid droplets

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0982-0

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39691780&oldid=1521575107"